CD163-blocking antibody

CD163-blocking antibodies are monoclonal antibodies designed to target and inhibit CD163 (scavenger receptor cysteine-rich type 1 protein M130), a cell surface glycoprotein primarily expressed on monocytes and macrophages, particularly immunosuppressive M2-like tumor-associated macrophages (TAMs). In the tumor microenvironment, CD163-expressing TAMs promote an immunosuppressive state, facilitate tumor growth, and limit the efficacy of immunotherapies. By blocking CD163, these antibodies prevent ligand binding and receptor-mediated signaling, thereby alleviating macrophage-mediated immunosuppression, restoring T-cell activation, and promoting anti-tumor immune responses. CD163-blocking antibodies are being investigated as potential immunotherapeutic strategies in various cancers, including synovial sarcoma, where they may target iron uptake in tumor-infiltrating leukocytes to overcome resistance to standard checkpoint blockades.

Other names

CD163 antibodyCD-163 antibodyCD 163 antibodyCD163-blocking monoclonal antibodyCD-163-blocking monoclonal antibodyCD 163-blocking monoclonal antibodyanti-CD163 antibodyanti-CD-163 antibodyanti-CD 163 antibodyanti-CD163 monoclonal antibodyanti-CD-163 monoclonal antibodyanti-CD 163 monoclonal antibody